PolyNovo Limited (CALZF)
- Previous Close
0.8100 - Open
0.8095 - Bid 0.7300 x 1000000
- Ask 0.8010 x 100000
- Day's Range
0.8095 - 0.8095 - 52 Week Range
0.6150 - 1.8200 - Volume
100 - Avg. Volume
882 - Market Cap (intraday)
559.583M - Beta (5Y Monthly) 1.56
- PE Ratio (TTM)
81.00 - EPS (TTM)
0.0100 - Earnings Date Aug 20, 2025 - Aug 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
polynovo.comRecent News: CALZF
View MorePerformance Overview: CALZF
Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CALZF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CALZF
View MoreValuation Measures
Market Cap
532.10M
Enterprise Value
523.45M
Trailing P/E
148.20
Forward P/E
59.17
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.56
Price/Book (mrq)
11.39
Enterprise Value/Revenue
6.94
Enterprise Value/EBITDA
87.20
Financial Highlights
Profitability and Income Statement
Profit Margin
5.11%
Return on Assets (ttm)
4.02%
Return on Equity (ttm)
8.17%
Revenue (ttm)
115.58M
Net Income Avi to Common (ttm)
5.91M
Diluted EPS (ttm)
0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
30.51M
Total Debt/Equity (mrq)
22.85%
Levered Free Cash Flow (ttm)
-15.65M